FOXO1 and diabetic kidney disease: In contrast, supplying exogenous rFGF4 mitigated DKD progression primarily by inhibiting oxidative stress to promote podocyte survival and glomerular function via the FGFR1-AMPK-FOXO1 signaling axis (Fig. 7f).